Haemonetics Corp - Company Profile
Powered by 
All the sales intelligence you need on Haemonetics Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Haemonetics Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Haemonetics Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Haemonetics Corporation (Haemonetics) is a global medical technology company focused on enhancing healthcare quality, effectiveness, and efficiency. The company specialises in developing innovative solutions for hospital technologies, plasma collection, and blood component collection. Haemonetics offers products such as donor management software, automated plasma collection systems, and blood management technologies. Notable brands include NexSys PCS and VASCADE. The company's products serve healthcare providers, plasma centers, and blood centers, addressing critical medical needs across various applications. Haemonetics operates through a network of channel partners and distribution networks to reach its customers. The company targets markets worldwide, with a significant presence in the United States and other regions. Haemonetics is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
125 Summer Street, Boston, Massachusetts, 02110
Website
www.haemonetics.com
Telephone
1 781 8487100
No of Employees
3,009
Industry
Medical Equipment
Ticker Symbol & Exchange
HAE (NYSE)
Revenue (2025)
$1.3B
-2%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-42%
(2025 vs 2024)
Market Cap*
$5.4B
Net Profit Margin (2025)
XYZ
-40.8%
(2025 vs 2024)
* As of and is in US$
Haemonetics Corp premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | - |
| Plasma | Fiber Optic Sensor Solutions | Elite |
| Automated plasma collection devices | Consulting Services for Blood Collectors | PCS |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In March, the company received US Food and Drug Administration (FDA) approval to expand the labeling for the VASCADE MVP XL venous vascular closure system. |
| 2026 | Regulatory Approval | In February, the company received US Food and Drug Administration (FDA) clearance for the NexSys PCS Plasma Collection System with Persona PLUS technology. |
| 2026 | Acquisitions/Mergers/Takeovers | In January, the company acquired Vivasure Medical Limited for EUR185 million. |
Competitor Comparison
| Key Parameters | Haemonetics Corp | Abbott Laboratories | Medtronic Plc | Fresenius SE & Co KGaA | LivaNova Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Ireland | Germany | United Kingdom |
| City | Boston | Abbott Park | Dublin | Bad Homburg | London |
| State/Province | Massachusetts | Illinois | - | Hessen | Greater London |
| No. of Employees | 3,009 | 115,000 | 95,000 | 178,486 | 3,300 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ellen M. Zane | Chairman | Executive Board | 2018 | 74 |
| Christopher A. Simon | Director; Chief Executive Officer; President | Executive Board | 2016 | 62 |
| James C. D’Arecca | Chief Financial Officer; Executive Vice President | Senior Management | 2022 | 55 |
| Frank W. Chan, Ph.D. | Chief Operating Officer; Executive Vice President | Senior Management | 2025 | 56 |
| Jan Hartmann, M.D. | Chief Medical Officer; Senior Vice President | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer